USD 61.81
(-11.41%)
Breakdown | 2023 | 2022 | 2021 |
---|---|---|---|
Revenue | -2.71 Million | -2.65 Million | - |
Cost of Revenue | 2.2 Million | 2.27 Million | 2.17 Million |
Gross Profit | -4.92 Million | -4.92 Million | -2.17 Million |
Operating Expenses | -2.71 Million | 1.13 Million | -1.78 Million |
Selling, General and Administrative Expenses | 1.35 Million | 1.13 Million | - |
Research and Development Expenses | - | - | - |
Other Expenses | - | - | -1.78 Million |
Cost and Expenses | 1.35 Million | 1.13 Million | 3.95 Million |
Operating Income | -4.14 Million | -3.92 Million | -3.95 Million |
Interest Expense | - | - | - |
Income Tax Expense | - | - | -3.00 |
Earnings before Tax | -4.14 Million | -3.92 Million | -4.03 Million |
Net Income | -4.14 Million | -3.92 Million | -4.03 Million |
Earnings Per Share Basic | -0.38 | -0.36 | -1.61 |
Earnings Per Share Diluted | -0.38 | -0.36 | -1.61 |
Weighted Average Shares Outstanding | 10.89 Million | 10.91 Million | 2.5 Million |
Weighted Average Shares Outstanding (Diluted) | 10.89 Million | 10.91 Million | 2.5 Million |
Gross Margin | 1.81 | 1.86 | - |
EBIT Margin | 1.52 | 1.48 | - |
Profit Margin | 1.52 | 1.48 | - |
EBITDA | -4.14 Million | -3.92 Million | -3.19 Million |
Earnings Before Tax Margin | 1.52 | 1.48 | - |
Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 |
---|---|---|---|---|---|---|
Revenue | 167.33 Thousand | -2.71 Million | 278.45 Thousand | 82.01 Thousand | -2.65 Million | 97.11 Thousand |
Cost of Revenue | 983.39 Thousand | 2.2 Million | 1.07 Million | 1.13 Million | 2.27 Million | 1.26 Million |
Gross Profit | -816.06 Thousand | -4.92 Million | -796.08 Thousand | -1.04 Million | -4.92 Million | -1.16 Million |
Operating Expenses | 4.19 Million | 1.35 Million | -5.30 | -32.51 | 1.13 Million | -101.02 |
Selling, General and Administrative Expenses | - | - | - | - | - | - |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | 4.19 Million | - | -5.30 | -32.51 | - | -101.02 |
Cost and Expenses | -3.2 Million | 1.35 Million | -1.47 Million | -2.66 Million | 1.13 Million | -9.8 Million |
Operating Income | 3.37 Million | -4.14 Million | -1.47 Million | -2.66 Million | -3.92 Million | -9.8 Million |
Interest Expense | - | - | - | - | - | - |
Income Tax Expense | - | - | -0.14 | -0.25 | - | -0.90 |
Earnings before Tax | 3.37 Million | -4.14 Million | -0.14 | -0.25 | -3.92 Million | -0.90 |
Net Income | 3.37 Million | -4.14 Million | 10.87 Million | - | -3.92 Million | 10.87 Million |
Earnings Per Share Basic | 0.31 | - | 1.00 | - | - | 1.62 |
Earnings Per Share Diluted | 0.31 | - | 1.00 | - | - | 1.62 |
Weighted Average Shares Outstanding | 10.87 Million | 10.89 Million | 10.87 Million | 10.87 Million | 10.91 Million | 6.7 Million |
Weighted Average Shares Outstanding (Diluted) | 10.87 Million | 10.89 Million | 10.87 Million | 10.87 Million | 10.91 Million | 6.7 Million |
Gross Margin | -4.88 | 1.81 | -2.86 | -12.80 | 1.86 | -12.01 |
EBIT Margin | 20.18 | - | 33.78 | 100.16 | - | 11.02 |
Profit Margin | 20.18 | 1.52 | 39.07 | - | 1.48 | 112.04 |
EBITDA | 3.37 Million | - | 9.4 Million | 8.21 Million | - | 1.07 Million |
Earnings Before Tax Margin | 20.18 | 1.52 | -5.30 | -32.51 | 1.48 | -101.02 |
0396
TRU
HALB
BAFN
PHARMAID
FUAPF